Clinical Trial: Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07238283) titled 'Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer' on Nov. 14.

Brief Summary: This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus nab-paclitaxel combined with gemcitabine as first-line treatment for advanced pancreatic cancer.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: First-line Treatment of Metastatic Pancreatic Cancer

Intervention: ...